A study in the American Journal of Transplantation revealed that evaluating the levels of the CXCL9 protein in the urine of kidney transplant patients may help identify those at risk of having kidney injury following transplant. "A noninvasive urine test to accurately monitor the risk of kidney rejection could dramatically reduce the need for biopsies and possibly enable doctors to safely reduce immunosuppressive therapy in some patients," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which funded the study.

Full Story:

Related Summaries